237 related articles for article (PubMed ID: 15464056)
1. Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis.
Takai S; Jin D; Muramatsu M; Okamoto Y; Miyazaki M
Eur J Pharmacol; 2004 Oct; 501(1-3):1-8. PubMed ID: 15464056
[TBL] [Abstract][Full Text] [Related]
2. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models.
Miyazaki M; Takai S; Jin D; Muramatsu M
Pharmacol Ther; 2006 Dec; 112(3):668-76. PubMed ID: 16837049
[TBL] [Abstract][Full Text] [Related]
3. Chymase: a new pharmacologic target in cardiovascular disease.
Bacani C; Frishman WH
Cardiol Rev; 2006; 14(4):187-93. PubMed ID: 16788331
[TBL] [Abstract][Full Text] [Related]
4. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases.
Liao Y; Husain A
Can J Cardiol; 1995 Aug; 11 Suppl F():13F-19F. PubMed ID: 7664213
[TBL] [Abstract][Full Text] [Related]
5. Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats.
Kanemitsu H; Takai S; Tsuneyoshi H; Nishina T; Yoshikawa K; Miyazaki M; Ikeda T; Komeda M
Hypertens Res; 2006 Jan; 29(1):57-64. PubMed ID: 16715654
[TBL] [Abstract][Full Text] [Related]
6. Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders?
Doggrell SA; Wanstall JC
Expert Opin Investig Drugs; 2003 Aug; 12(8):1429-32. PubMed ID: 12882628
[TBL] [Abstract][Full Text] [Related]
7. Vascular chymase: pathophysiological role and therapeutic potential of inhibition.
Doggrell SA; Wanstall JC
Cardiovasc Res; 2004 Mar; 61(4):653-62. PubMed ID: 14985062
[TBL] [Abstract][Full Text] [Related]
8. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters.
Takai S; Jin D; Sakaguchi M; Katayama S; Muramatsu M; Sakaguchi M; Matsumura E; Kim S; Miyazaki M
J Pharmacol Exp Ther; 2003 Apr; 305(1):17-23. PubMed ID: 12649348
[TBL] [Abstract][Full Text] [Related]
9. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure.
Matsumoto T; Wada A; Tsutamoto T; Ohnishi M; Isono T; Kinoshita M
Circulation; 2003 May; 107(20):2555-8. PubMed ID: 12742989
[TBL] [Abstract][Full Text] [Related]
10. A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[,4-dioxo-1-phenyl-7-(2-pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury.
Takai S; Sakonjo H; Fukuda K; Jin D; Sakaguchi M; Kamoshita K; Ishida K; Sukenaga Y; Miyazaki M
J Pharmacol Exp Ther; 2003 Feb; 304(2):841-4. PubMed ID: 12538841
[TBL] [Abstract][Full Text] [Related]
11. [Role of chymase in vascular diseases and the efficacy of chymase inhibitor].
Takai S
Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):111-20. PubMed ID: 12890897
[TBL] [Abstract][Full Text] [Related]
12. Effect of chymase inhibitor on vascular proliferation.
Takai S; Miyazaki M
Jpn J Pharmacol; 2002 Nov; 90(3):223-7. PubMed ID: 12499576
[TBL] [Abstract][Full Text] [Related]
13. Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs.
Jin D; Ueda H; Takai S; Okamoto Y; Muramatsu M; Sakaguchi M; Shibahara N; Katsuoka Y; Miyazaki M
J Am Soc Nephrol; 2005 Apr; 16(4):1024-34. PubMed ID: 15744002
[TBL] [Abstract][Full Text] [Related]
14. Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats.
Kirimura K; Takai S; Jin D; Muramatsu M; Kishi K; Yoshikawa K; Nakabayashi M; Mino Y; Miyazaki M
Hypertens Res; 2005 May; 28(5):457-64. PubMed ID: 16156510
[TBL] [Abstract][Full Text] [Related]
15. [Pathophysiological roles of chymase and effects of chymase inhibitor].
Takai S; Jin D; Miyazaki M
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():41P-47P. PubMed ID: 10629853
[TBL] [Abstract][Full Text] [Related]
16. [Role of angiotensin II-forming enzymes, angiotensin-converting enzyme and chymase].
Takai S; Miyazaki M
Nihon Rinsho; 1999 May; 57(5):1078-83. PubMed ID: 10361438
[TBL] [Abstract][Full Text] [Related]
17. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery.
Nishimoto M; Takai S; Sawada Y; Yuda A; Kondo K; Yamada M; Jin D; Sakaguchi M; Asada K; Sasaki S; Miyazaki M
J Thorac Cardiovasc Surg; 2001 Apr; 121(4):729-34. PubMed ID: 11279415
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of chymase reduces vascular proliferation in dog grafted veins.
Takai S; Yuda A; Jin D; Nishimoto M; Sakagichi M; Sasaki S; Miyazaki M
FEBS Lett; 2000 Feb; 467(2-3):141-4. PubMed ID: 10675526
[TBL] [Abstract][Full Text] [Related]
19. Local angiotensin II-generating system in vascular tissues: the roles of chymase.
Miyazaki M; Takai S
Hypertens Res; 2001 May; 24(3):189-93. PubMed ID: 11409639
[TBL] [Abstract][Full Text] [Related]
20. A novel therapeutic strategy against vascular disorders with chymase inhibitor.
Takai S; Miyazaki M
Curr Vasc Pharmacol; 2003 Jun; 1(2):217-24. PubMed ID: 15320845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
